Drug Testing Locations - Low Moor, VA

Drug Testing in Low Moor, VA

Low Moor, Virginia Statistics

In Low Moor, Alleghany County saw a 12% increase in opioid-related overdoses reported in 2022.

In 2022, Low Moor's drug rehab facilities treated over 150 individuals suffering from substance abuse.

The Alleghany County Sheriff's Office registered a 15% rise in drug possession arrests in Low Moor in 2022.

Low Moor reported a 10% decrease in teen drug-related issues within Alleghany County EDC programs in 2021.

In 2021, Alleghany County opioid prescriptions per capita were among the highest in Virginia, affecting Low Moor communities.

How does the body eliminate Drugs

Drug elimination is the sum of the processes of removing an administered drug from the body. In the pharmacokinetic ADME scheme (absorption, distribution, metabolism, and excretion), it is frequently considered to encompass both metabolism and excretion. Hydrophobic drugs, to be excreted, must undergo metabolic modification making them more polar. Hydrophilic drugs, on the other hand, can undergo excretion directly, without the need for metabolic changes to their molecular structures.

Although many sites of metabolism and excretion exist, the chief organ of metabolism is the liver, while the organ primarily tasked with excretion is the kidney. Any significant dysfunction in either organ can result in the accumulation of the drug or its metabolites in toxic concentrations.

A variety of other factors impact elimination — intrinsic drug properties, such as polarity, size, or pKa. Also other factors include genetic variation among individuals, disease states affecting other organs, and pathways involved in the way the drug distributes through the body, such as first-pass metabolism.

Issues of Concern

Drug elimination is the removal of an administered drug from the body. It is accomplished in two ways, either by excretion of an unmetabolized drug in its intact form or by metabolic biotransformation followed by excretion. While excretion is primarily carried out by the kidneys, other organ systems are involved as well. Similarly, the liver is the primary site of biotransformation, yet extrahepatic metabolism takes place in a variety of organ systems affecting multiple drugs.

Given the multiple organ systems and the variety of metabolic transformations present, drug elimination can entail a significant degree of complexity. Hydrophilic drugs are typically directly excreted by the kidneys, while hydrophobic drugs undergo biotransformation before excretion. The purpose here is twofold – biotransformation serves both detoxify the exogenous substances as well as to increase their hydrophilicity, ensuring their elimination via the kidneys.

Two broad metabolic pathways of hepatic drug transformation exist. Phase I is the direct modification of the target molecule, whereas phase II entails conjugation of the target to a polar molecule of low molecular weight. Phase I prepare the drug to enter phase II, but single-phase metabolism also exists.

Phase I involves oxidation, reduction, and hydrolysis of the exogenous molecule. These reactions are accomplished by hepatic microsomal enzymes, which reside in the smooth endoplasmic reticulum of the hepatocytes. Best known among them is the cytochrome P450 system, whose enzymes are predominantly involved in oxidative metabolism. Within the cytochrome P450 family (CYP), the enzyme responsible for the metabolism of more than 50% of existing drugs is the CYP3A4. Its activity encompasses various classes of medications, including opioids, immunosuppressants, antihistamines, and benzodiazepines. The enzymes can also be induced or inhibited by a variety of substances they interact with, including pharmaceuticals. The increase in metabolic activity with CYP induction results in a diminished activity of drugs targeted by that particular isoform. Conversely, CYP inhibition will result in increased drug plasma concentration, potentially leading toxicity. The CYP3A4 is induced by phenytoin, phenobarbital, and St. John's wort, while diltiazem, erythromycin, and grapefruit inhibit it. Caution is, therefore, necessary when administering CYP3A4-metabolized drugs in the presence of any of the inhibitors or inducers.

Phase II consists of covalent bonding of polar groups to nonpolar molecules to render them water-soluble and allow renal or biliary excretion. Target molecules enter phase II directly or via initial processing through phase I. A variety of polar adjuncts is transferred, including amino acids, glucuronic acid, glutathione, acetate, and sulfate. Glucuronidation is one of the major pathways of phase II biotransformation. The UDP-glucuronosyltransferase (UGT) enzyme family performs this activity. Typically, glucuronide derivatives possess less or no activity of the original drug, but in some cases, pharmacologically active compounds result. Morphine-6-glucuronide is a phase II metabolite of morphine with significant analgesic activity. As with the CYP enzymes, inducers, and inhibitors of phase II, enzymes exist and may influence the efficacy of drugs that rely on conjugation before excretion.

The first-pass effect is a feature of hepatic metabolism that also plays a role in the elimination of multiple drugs. Here, the enteric consumed drugs are exposed directly to the liver via the portal vein, where they undergo biotransformation before entering the systemic circulation. This activity reduces the bioavailability and needs to be factored into the dose administered to the patient. Intravenously administered drugs are not subject to the first-pass effect.

Extrahepatic drug metabolism takes place in the GI tract, kidneys, lungs, plasma, and skin.

Renal excretion completes the process of elimination that begins in the liver. Polar drugs or their metabolites get filtered in the kidneys and typically do not undergo reabsorption. They subsequently get excreted in the urine. Urinary pH has a significant impact on excretion, as drug ionization changes depending on the alkaline or acidic environment. Increased excretion occurs with weakly acidic drugs in basic urine and weakly basic drugs in acidic urine.

Excretion in the bile is another significant form of drug elimination. The liver can actively secrete ionized drugs with a molecular weight greater than 300 g/mol into bile, from where they reach the digestive tract and are either eliminated in feces or reabsorbed as part of the enterohepatic cycle.

Other pathways of excretion include the lungs, breast milk, sweat, saliva, and tears

Employers in Low Moor, VA & Drug Testing Policies

In Low Moor, VA, employers adhere to strict drug testing policies to ensure a safe workplace. Regular drug screenings are part of the hiring process, and random testing is conducted periodically. This is in line with state requirements as outlined by the Virginia Department of Labor here. Companies often partner with local clinics for efficient and confidential testing services. These measures not only promote safety but also enhance productivity.

Government Efforts with Drug Problems in Low Moor, VA

The government has been proactive in addressing drug issues in Low Moor, VA, through various initiatives. A key player is the Virginia Department of Health, which provides resources and funding for local substance abuse treatment and prevention programs. Find more about their efforts here. Additionally, Alleghany County collaborates with the DEA and other federal agencies for intelligence sharing and joint operations, aiming to curb drug trafficking and distribution networks.

Local Drug Busts & News in Low Moor, VA

Recent local drug busts in Low Moor, VA, have highlighted ongoing issues with narcotics distribution. In July 2022, the Alleghany County Sheriff's Office seized over $500,000 worth of illicit drugs in a major operation, resulting in several arrests. These activities underscore the need for continued vigilance and cooperation amongst law enforcement agencies to combat drug trafficking effectively. Such events also spark community involvement in awareness campaigns and educational programs to prevent substance abuse.

Occupational Health Services

Accredited Drug Testing offers fast, reliable employment screening services in Low Moor, VA. Trusted by employers nationwide for accurate results and exceptional service.

Virginia DOT/Non DOT Physicals

Virginia Vision Tests

Virginia Audiograms

Virginia Respirator Fit Tests

Virginia Lift Tests

Virginia Background Checks

Clinical Testing Services

TB Testing in VA

Diabetes Testing in VA

Infectious Disease Testing in VA

Sickle Cell Anemia Testing in VA

Women/Men's Health Testing in VA

Resources & Citations

Virginia Department of Health

Virginia Department of Labor and Industry

Drug Enforcement Administration

SAMHSA National Helpline

National Institute on Drug Abuse

Radical Recovery

Alleghany Highlands Community Services

Virginia Alcohol Safety Action Program

Drug Testing Near Low Moor, VA

Piney Mountain, VA

Millboro, VA

Fincastle, VA

Warm Springs, VA

Bacova, VA

Mitchelltown, VA

Oriskany, VA

Alleghany, VA

Healing Springs, VA

Eagle Rock, VA

Callaghan, VA

Covington, VA

Iron Gate, VA

Glen Wilton, VA

Clifton Forge, VA

Frequently Asked Questions

Customer Reviews